Yuhan Corporation and Cyrus Therapeutics Collaborate to Develop Small Molecule Anticancer Targeted Therapies

2023-09-06 02:19:45

Expect synergy between Cyrus’ anti-cancer drug discovery capabilities and Yuhan’s translational clinical research capabilities
Looking forward to quickly discovering the second Lexraza with global competitiveness

From left, Kim Byung-moon, CEO of Cyrus Therapeutics, and Cho Wook-je, CEO of Yuhan Corporation (Photo Credit=Yuhan Corporation)

[바이오타임즈] Yuhan Corp. (CEO Wook-Je Cho) announced that it had signed a memorandum of understanding (MOU) with Cyrus Therapeutics Co., Ltd. (CEO Byung-Moon Kim) to develop an innovative small-molecule anti-cancer drug.

Through this MOU, the two companies plan to use Cyrus Therapeutics’ small molecule targeted therapy development and small molecule decomposer development technology to carry out basic research on anticancer drug development, joint development of anticancer drug candidates, and technology transfer and commercialization cooperation.

Cyrus Therapeutics is a bio company specializing in new drug development that possesses both innovative small molecule therapeutic development and targeted proteolysis (TPD) development technologies, a new modality. It has attracted attention through the announcement of new drug candidates.

Cho Wook-je, CEO of Yuhan Corporation, said, “We look forward to rapidly discovering the second Lexraza in the future by developing a globally competitive anti-cancer drug through cooperation with Cyrus, which has a high competency in developing small molecule anti-cancer drugs. In particular, the anti-cancer field is an area where Yuhan has accumulated a lot of know-how through the development experience of Lexraza, and we expect that rapid development will be possible through cooperation between the two companies.”

Byung-moon Kim, CEO of Cyrus, said, “We expect that Cyrus’ anti-cancer drug discovery capabilities and Yuhan’s translational clinical research capabilities will be combined to create a world-class new drug with great synergy, creating an exemplary case of win-win for both companies.”

[바이오타임즈=김수진 기자] [email protected]

© Biotimes Unauthorized reproduction and redistribution prohibited

1693972088
#Yuhan #Corporation #Cyrus #Therapeutics #Collaborate #Develop #Small #Molecule #Anticancer #Targeted #Therapies